← FDA DRUG APPROVALS

FDA ANDA · ANDA206964

ASPIRIN AND DIPYRIDAMOLE

Sponsor: ANI PHARMS

APPLICATION
ANDA206964
TYPE
ANDA
ORIGINAL APPROVAL
2017-01-18
LATEST ACTION
2024-04-15
ROUTE
ORAL
DOSAGE FORM
CAPSULE, EXTENDED RELEASE
MARKETING STATUS
Discontinued

Products

ASPIRIN AND DIPYRIDAMOLEDiscontinued
ASPIRIN 25MG, DIPYRIDAMOLE 200MG · CAPSULE, EXTENDED RELEASE · ORAL

Approval history

2024-04-15Labeling · Supplement 8 · standardAP
2024-04-15Labeling · Supplement 10 · standardAP
2019-04-16Labeling · Supplement 7 · standardAP
2017-01-18UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →